<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107377</url>
  </required_header>
  <id_info>
    <org_study_id>EVO-003</org_study_id>
    <nct_id>NCT03107377</nct_id>
  </id_info>
  <brief_title>Phase 2B/3 Double-blinded Placebo-controlled</brief_title>
  <official_title>Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evofem Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research Management, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evofem Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2B double-blind placebo-controlled efficacy trial of EVO100 (previously known as&#xD;
      Amphora ® Gel) for the prevention of acquisition of urogenital Chlamydia trachomatis&#xD;
      infection&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary: To determine if intravaginal EVO100 reduces the risk of urogenital Chlamydia&#xD;
      trachomatis (CT) infection.&#xD;
&#xD;
      Secondary: To determine if intravaginal EVO100 reduces the risk of urogenital Neisseria&#xD;
      gonorrhoeae (GC) infection.&#xD;
&#xD;
      Exploratory:To determine if EVO100 use rate (subject adherence to instructed use) has an&#xD;
      effect on proportion of subjects who experience CT or GC infection during the study&#xD;
      intervention period.&#xD;
&#xD;
      Primary Outcome Measures: Proportion of subjects who experience urogenital CT infection&#xD;
      during the study intervention period (incident infection of CT).&#xD;
&#xD;
      Secondary Outcome Measures: Proportion of subjects who experience urogenital GC infection&#xD;
      during the study intervention period (incident infection of GC).&#xD;
&#xD;
      Exploratory Outcome Measures:&#xD;
&#xD;
        -  Compliance with EVO100 usage during study (rate of product use adherence).&#xD;
&#xD;
        -  Sensitivity analyses of the primary parameter (proportion of subjects who experience at&#xD;
           least one CT or GC infection during the study intervention period) will be performed for&#xD;
           the following:&#xD;
&#xD;
        -  Subjects with ≥20%, ≥40%, ≥60% and ≥80% product use adherence&#xD;
&#xD;
        -  Subject Satisfaction&#xD;
&#xD;
        -  Sexual satisfaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Actual">August 22, 2019</completion_date>
  <primary_completion_date type="Actual">August 22, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2B double-blind placebo-controlled efficacy trial of EVO100 for the prevention of acquisition of urogenital Chlamydia trachomatis infection</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind placebo-controlled efficacy trial of EVO100</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urogenital CT Infection</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urogenital GC Infection</measure>
    <time_frame>16 weeks</time_frame>
    <description>Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance With EVO100 and Sensitivity Analyses (Part I)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Summary of Coital Events during treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject Satisfaction With Product</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sexual Satisfaction</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance With EVO100 and Sensitivity Analyses</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance With EVO100 and Sensitivity Analyses</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance With EVO100 and Sensitivity Analyses (Part II)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Summary of number of applicators used via eDiary</description>
  </other_outcome>
  <other_outcome>
    <measure>Compliance With EVO100 and Sensitivity Analyses (Part III)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Study product adherence</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">860</enrollment>
  <condition>Chlamydia Trachomatis Infection</condition>
  <arm_group>
    <arm_group_label>EVO100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVO100</intervention_name>
    <description>5 g dose applied up to 1 hour prior to coitus</description>
    <arm_group_label>EVO100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 g dose applied up to 1 hour prior to coitus</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy female subjects between 18 and 45 years, inclusive&#xD;
&#xD;
          2. Ability to understand the consent process and procedures&#xD;
&#xD;
          3. Subjects agree to be available for all study visits&#xD;
&#xD;
          4. Written informed consent in accordance with institutional guidelines&#xD;
&#xD;
          5. Negative pregnancy test&#xD;
&#xD;
          6. Negative CT and GC NAAT tests OR positive CT or GC NAAT and receives standard of care&#xD;
             (SOC) treatment&#xD;
&#xD;
          7. Agree to use a woman-controlled method of contraception, such as oral contraceptives,&#xD;
             vaginal ring, birth control implants, IUDs, or tubal ligation (with the exception of&#xD;
             spermicides, diaphragms, or any vaginally applied or inserted products containing&#xD;
             nonoxynol-9). Condom use only is not an acceptable form of contraception for this&#xD;
             study.&#xD;
&#xD;
          8. Able and willing to comply with all study procedures&#xD;
&#xD;
          9. Documented (as part of a retrievable medical record) CT or GC infection within 16&#xD;
             weeks prior to enrollment&#xD;
&#xD;
         10. Reports vaginal sexual intercourse with a male partner at least 3 times per month in&#xD;
             the previous month and anticipates vaginal sexual intercourse regularly for the&#xD;
             duration of the study&#xD;
&#xD;
         11. Agree to abstain from douching or any form of vaginal suppository use (other than&#xD;
             study product) during course of study&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in any study with an investigational compound or device within 30 days&#xD;
             prior to signing informed consent&#xD;
&#xD;
          2. In the opinion of the Investigator, have a history of substance abuse in the last 12&#xD;
             months&#xD;
&#xD;
          3. In the opinion of the Investigator, have issues, conditions, or concerns that may&#xD;
             compromise the safety of the subject, impact the subject's compliance with the&#xD;
             protocol requirements, or confound the reliability of the data acquired&#xD;
&#xD;
          4. Be an Evofem, ClinicalRM, or clinical site employee regardless of direct involvement&#xD;
             in research activities, or their close relative&#xD;
&#xD;
          5. Pregnant (or actively trying to become pregnant), or breast-feeding&#xD;
&#xD;
          6. Women who have undergone a total hysterectomy (had uterus and cervix removed)&#xD;
&#xD;
          7. Inability to provide informed consent&#xD;
&#xD;
          8. A subject with a history or expectation of noncompliance with medications or&#xD;
             intervention protocol&#xD;
&#xD;
          9. Have engaged in sexual intercourse, douching or used of any form of vaginal&#xD;
             suppository or intravaginal device for 24 hours prior to enrollment (may be enrolled&#xD;
             at a later date if all other criteria are met)&#xD;
&#xD;
         10. Menstruating at enrollment (may be enrolled at a later date if all other criteria are&#xD;
             met)&#xD;
&#xD;
         11. Women who are currently being treated, or have been treated, for a period of 14 days&#xD;
             prior to enrollment, with specific antibiotics known to be used for the treatment of&#xD;
             CT or GC:&#xD;
&#xD;
               1. Azithromycin&#xD;
&#xD;
               2. Erythromycin&#xD;
&#xD;
               3. Tetracycline&#xD;
&#xD;
               4. Minocycline&#xD;
&#xD;
               5. Doxycycline&#xD;
&#xD;
               6. Levofloxacin&#xD;
&#xD;
               7. Ofloxacin&#xD;
&#xD;
               8. Ceftriaxone&#xD;
&#xD;
               9. Cefixime&#xD;
&#xD;
         12. In the opinion of the Investigator, has signs/symptoms that indicate persistence of&#xD;
             chlamydia or gonorrhea infection diagnosed at screening, new interval infection and/or&#xD;
             a failure to comply with or complete the prescribed treatment regimen following a&#xD;
             positive screening NAAT.&#xD;
&#xD;
         13. Women who regularly use douches, vaginal medications, products, or suppositories&#xD;
&#xD;
         14. Women who are currently using contraceptive products that are directly delivered to&#xD;
             the vaginal mucosa, such as diaphragms, vaginal rings (e.g. NuvaRing®), spermicides,&#xD;
             or any vaginally applied or inserted products containing nonoxynol-9.&#xD;
&#xD;
         15. Children, pregnant women, prisoners, and other vulnerable populations&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>844 female subjects, ages 18-45.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Culwell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Evofem Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile OB-GYN, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eclipse Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Center for Clinical Research</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Clinical Research</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research - Wake Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus Medical Group, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood of Southern New England</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Health Research Center</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Care Clinical Research LLC</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute - IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renew Health Clinical Research, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Richmond Hill</city>
        <state>Georgia</state>
        <zip>31324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASR, LLC</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DM Clinical Research</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley OB-GYN</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedPharmics, LLD</name>
      <address>
        <city>Biloxi</city>
        <state>Mississippi</state>
        <zip>39531</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of MS Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Obstetrical Charity Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bosque Women's Care</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research, Inc. - Wilmington Health</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>41073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Southeastern Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invocare Clinical Research Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adams Patterson OB/GYN, Medical Research Center of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Family Physicians</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gadolin Research</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CityDoc Urgent Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Network America</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studios, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discovery MM Services, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.E.Tx. Family Planning and Cancer Screening (SOGA)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Family Medicine</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neere Bhatia, MD OB/GYN</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Group for Women</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>June 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03107377/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03107377/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EVO100</title>
          <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="434"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="335"/>
                <participants group_id="P2" count="335"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population</population>
      <group_list>
        <group group_id="B1">
          <title>EVO100</title>
          <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100l: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="426"/>
            <count group_id="B2" value="434"/>
            <count group_id="B3" value="860"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="860"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.82" spread="7.112"/>
                    <measurement group_id="B2" value="27.53" spread="6.722"/>
                    <measurement group_id="B3" value="27.68" spread="6.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="860"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="577"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="426"/>
                    <measurement group_id="B2" value="434"/>
                    <measurement group_id="B3" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urogenital CT Infection</title>
        <description>Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT Population - All CT Analysis Eligible Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Urogenital CT Infection</title>
          <description>Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT).</description>
          <population>mITT Population - All CT Analysis Eligible Subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0256</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.02</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urogenital GC Infection</title>
        <description>Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT Population - All GC Analysis Eligible Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Urogenital GC Infection</title>
          <description>Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC).</description>
          <population>mITT Population - All GC Analysis Eligible Subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0316</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With EVO100 and Sensitivity Analyses (Part I)</title>
        <description>Summary of Coital Events during treatment</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With EVO100 and Sensitivity Analyses (Part I)</title>
          <description>Summary of Coital Events during treatment</description>
          <population>mITT population</population>
          <units>Coital Events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="14.38"/>
                    <measurement group_id="O2" value="16.3" spread="15.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject Satisfaction With Product</title>
        <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
        <time_frame>16 weeks</time_frame>
        <population>Subject Satisfaction by Visit (mITT population)</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction With Product</title>
          <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
          <population>Subject Satisfaction by Visit (mITT population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Very satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sexual Satisfaction</title>
        <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
        <time_frame>16 weeks</time_frame>
        <population>Subjects sexual satisfaction by Visit - mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Satisfaction</title>
          <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
          <population>Subjects sexual satisfaction by Visit - mITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="267"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>My sex life is a lot better than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>My sex life is a little better than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>My sex life is no different than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>My sex life is a little worse than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>My sex life is a lot worse than before</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With EVO100 and Sensitivity Analyses</title>
        <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT Population - All CT Analysis Eligible Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With EVO100 and Sensitivity Analyses</title>
          <description>The proportion of subjects who experienced at least one CT infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
          <population>mITT Population - All CT Analysis Eligible Subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># of subjects w/ CT infection &amp; 0% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; &gt;0% &lt;20% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; &gt;=20% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; &gt;=40% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; &gt;=60% adhere</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; &gt;=80% adhere</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>of subjects w/ CT infection &amp; =100% adhere</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with =0% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;0% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=20% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.6278</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=40% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.6404</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=60% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.5008</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=80% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.1818</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with =100% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With EVO100 and Sensitivity Analyses</title>
        <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT Population - All GC Analysis Eligible Subjects</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With EVO100 and Sensitivity Analyses</title>
          <description>The proportion of subjects who experienced at least one GC infection during the study Intervention Period was summarized by treatment group using the mITT population and subject adherence rates.</description>
          <population>mITT Population - All GC Analysis Eligible Subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title># of subjects with GC infection &amp; 0% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects w/ GC infection &amp; &gt;0% &lt;20% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects with GC infection &amp; &gt;=20% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects with GC infection &amp; &gt;=40% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects with GC infection &amp; &gt;=60% adh</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects with GC infection &amp; &gt;=80% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title># of subjects with GC infection &amp; =100% adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with =0% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;0% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4375</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=20% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4444</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=60% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1836</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with &gt;=80% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5006</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A comparison of infection rates between the treatment arms amongst subjects with =100% adherence</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With EVO100 and Sensitivity Analyses (Part II)</title>
        <description>Summary of number of applicators used via eDiary</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With EVO100 and Sensitivity Analyses (Part II)</title>
          <description>Summary of number of applicators used via eDiary</description>
          <population>mITT population</population>
          <units>Number of Applicators</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="12.95"/>
                    <measurement group_id="O2" value="13.5" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Compliance With EVO100 and Sensitivity Analyses (Part III)</title>
        <description>Study product adherence</description>
        <time_frame>16 weeks</time_frame>
        <population>mITT population</population>
        <group_list>
          <group group_id="O1">
            <title>EVO100</title>
            <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With EVO100 and Sensitivity Analyses (Part III)</title>
          <description>Study product adherence</description>
          <population>mITT population</population>
          <units>% of sex acts where study product used</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="360"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="27.14"/>
                    <measurement group_id="O2" value="78.3" spread="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <desc>For the 860 subjects randomized into the study, 764 had documented use of study product and were a part of the safety population/analyzed for safety purposes. Amongst these 764 subjects, no deaths were reported during the course of the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>EVO100</title>
          <description>A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
EVO100: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.&#xD;
Placebo: 5 g dose applied up to 1 hour prior to coitus</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="376"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="376"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="376"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial Vaginosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="376"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="376"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Candidiasis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="376"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="376"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="388"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="376"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For the Adverse Event Section: There were no All-Cause Mortalities to Report</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Evofem</organization>
      <phone>858-550-1900</phone>
      <email>kculwell@evofem.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

